Bausch Health Cos (NYSE:BHC) Insider Aimee Lenar Sells 36,827 Shares

Key Points

• Insider sale: Aimee Lenar sold 36,827 Bausch Health shares at an average price of $7.03, generating approximately $258,894. The transaction, conducted under a Rule 10b5-1 plan, reduced her ownership by 9.91% to 334,853 shares.
• Financial performance: Bausch Health reported quarterly EPS of $1.26, exceeding analyst expectations of $0.96, while revenue of $2.83 billion also topped estimates. However, the company posted a negative net margin and highly negative return on equity.
• Market and analyst view: Shares recently traded at $6.84, while analysts’ consensus rating is “Reduce” with an average price target of $8.00. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) insider Aimee Lenar sold 36,827 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total transaction of $258,893.81. Following the sale, the insider directly owned 334,853 shares in the company, valued at $2,354,016.59. This trade represents a 9.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bausch Health Cos Price Performance

Shares of Bausch Health Cos stock traded down $0.05 during midday trading on Thursday, reaching $6.84. The company had a trading volume of 1,904,329 shares, compared to its average volume of 2,545,744. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. The stock has a fifty day simple moving average of $5.30 and a 200 day simple moving average of $5.45. Bausch Health Cos Inc. has a 1-year low of $4.33 and a 1-year high of $8.00. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -2.31 and a beta of 0.38.

Bausch Health Cos (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, beating analysts' consensus estimates of $0.96 by $0.30. The firm had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. As a group, equities research analysts forecast that Bausch Health Cos Inc. will post 4.24 earnings per share for the current year.

Hedge Funds Weigh In On Bausch Health Cos

Hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio acquired a new position in Bausch Health Cos in the second quarter valued at about $2,565,000. Bank of America Corp DE acquired a new stake in shares of Bausch Health Cos during the second quarter worth about $2,816,000. Paulson & CO. Inc. bought a new position in shares of Bausch Health Cos during the 2nd quarter valued at about $361,151,000. Man Group plc bought a new position in shares of Bausch Health Cos during the 2nd quarter valued at about $7,157,000. Finally, Biglari Capital CORP. acquired a new position in shares of Bausch Health Cos in the 2nd quarter valued at approximately $202,475,000. Institutional investors and hedge funds own 78.65% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on BHC shares. Weiss Ratings raised Bausch Health Cos from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, July 31st. Jefferies Financial Group raised shares of Bausch Health Cos to a "hold" rating in a research note on Wednesday, July 22nd. Wall Street Zen upgraded shares of Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 1st. Zacks Research downgraded shares of Bausch Health Cos from a "hold" rating to a "strong sell" rating in a research note on Friday, July 24th. Finally, Royal Bank Of Canada cut their price objective on shares of Bausch Health Cos from $10.00 to $9.00 and set a "sector perform" rating on the stock in a report on Monday, April 27th. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Bausch Health Cos presently has a consensus rating of "Reduce" and an average price target of $8.00.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source